Clinicodemographic variables
| Variable . | Entire cohort . | Consolidation cohort . |
|---|---|---|
| N = 559∗ . | n = 385∗ . | |
| Gender | ||
| Female | 262 (46.9%) | 167 (43.4%) |
| Male | 297 (53.1%) | 218 (56.6%) |
| Age at diagnosis, y | 63 (53.5, 72) | 61 (52.0, 69) |
| KPS score | ||
| <70 | 197 (35.2%) | 121 (31.4%) |
| ≥70 | 362 (64.8%) | 264 (68.6%) |
| MSKCC RPA class | ||
| 1 | 102 (18.2%) | 84 (21.8%) |
| 2 | 321 (57.4%) | 231 (60.0%) |
| 3 | 136 (24.3%) | 70 (18.2%) |
| Date of diagnosis by decade | ||
| 1980s | 11 (2.0%) | 9 (2.3%) |
| 1990s | 112 (20.0%) | 70 (18.2%) |
| 2000s | 197 (35.2%) | 129 (33.5%) |
| 2010-2020s | 239 (42.8%) | 177 (46.0%) |
| Induction regimen | ||
| MPV | 144 (25.8%) | 95 (24.7%) |
| R-MPV | 257 (46.0%) | 211 (54.8%) |
| Other | 158 (28.3%) | 79 (20.5%) |
| MTX-containing | 54 | 72 |
| Non-MTX–containing | 27 | 7 |
| Consolidation regimen | ||
| NMC | 167 (30.4%) | 167 (43.4%) |
| AHCT | 79 (14.4%) | 79 (20.5%) |
| None | 165 (30.0%) | |
| Other | 23 (4.2%) | 23 (6.0%) |
| RD-WBRT | 55 (10.0%) | 55 (14.3%) |
| SD-WBRT | 61 (11.1%) | 61 (15.8%) |
| Unknown | 9 |
| Variable . | Entire cohort . | Consolidation cohort . |
|---|---|---|
| N = 559∗ . | n = 385∗ . | |
| Gender | ||
| Female | 262 (46.9%) | 167 (43.4%) |
| Male | 297 (53.1%) | 218 (56.6%) |
| Age at diagnosis, y | 63 (53.5, 72) | 61 (52.0, 69) |
| KPS score | ||
| <70 | 197 (35.2%) | 121 (31.4%) |
| ≥70 | 362 (64.8%) | 264 (68.6%) |
| MSKCC RPA class | ||
| 1 | 102 (18.2%) | 84 (21.8%) |
| 2 | 321 (57.4%) | 231 (60.0%) |
| 3 | 136 (24.3%) | 70 (18.2%) |
| Date of diagnosis by decade | ||
| 1980s | 11 (2.0%) | 9 (2.3%) |
| 1990s | 112 (20.0%) | 70 (18.2%) |
| 2000s | 197 (35.2%) | 129 (33.5%) |
| 2010-2020s | 239 (42.8%) | 177 (46.0%) |
| Induction regimen | ||
| MPV | 144 (25.8%) | 95 (24.7%) |
| R-MPV | 257 (46.0%) | 211 (54.8%) |
| Other | 158 (28.3%) | 79 (20.5%) |
| MTX-containing | 54 | 72 |
| Non-MTX–containing | 27 | 7 |
| Consolidation regimen | ||
| NMC | 167 (30.4%) | 167 (43.4%) |
| AHCT | 79 (14.4%) | 79 (20.5%) |
| None | 165 (30.0%) | |
| Other | 23 (4.2%) | 23 (6.0%) |
| RD-WBRT | 55 (10.0%) | 55 (14.3%) |
| SD-WBRT | 61 (11.1%) | 61 (15.8%) |
| Unknown | 9 |
KPS, Karnofsky Performance Status; MSKCC RPA, Memorial Sloan Kettering recursive portioning analysis; MPV, methotrexate, procarbazine, vincristine; R, rituximab; MTX, methotrexate; AHCT, autologous hematopoietic cell transplant; RD-WBRT, reduced-dose whole-brain radiotherapy; SD-WBRT, standard dose whole-brain radiotherapy; IQR, interquartile range. Common induction regimens categorized under “other” included methotrexate monotherapy and combination methotrexate-containing therapy either with or without rituximab (eg, methotrexate-temozolomide-rituximab). Common consolidation regimens categorized under “other” included maintenance methotrexate, maintenance ibrutinib, and focal radiotherapy.
IQR, interquartile range; MTX, methotrexate; R, rituximab.
n (%); median (IQR).